Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...

Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial. The biotech is planning to launch a late-stage program for the drug later ...

Iran’s new ruler is already a marked man. U.S. President Donald Trump has said Mojtaba Khamenei, who replaced his slain father, Ayatollah Ali Khamenei, as the country’s supreme leader, is an ...

Astronomers have produced the most detailed map yet of dark matter, revealing the invisible framework that shaped the Universe long before stars and galaxies formed. Using powerful new observations ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. After the ...

The Bermuda Triangle may not be the biggest mystery of the Atlantic. In a new study published in the journal Geophysical Research Letters, scientists believe they have discovered the reason why ...

Anchor your business to a stubborn, real-world problem customers cannot ignore. Replace hustle with systems that standardize decisions, data flow and accountability. Ambition isn’t what holds ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...

First, there was the Pegasus. Nike’s neutral everyday trainer has run circles around the competition for literal decades. According to Strava, it remains the most popular shoe across the platform, ...